VALIDATION OF A STMN2-BASED BIOMARKER FOR ALS PATIENT IDENTIFICATION AND TARGET ENGAGEMENT IN CLINICAL STUDIES
$0FY2022Defense Health AgencyDOD
Quralis Corporation, Cambridge MA
Investigators
View source on USAspending →VALIDATION OF A STMN2-BASED BIOMARKER FOR ALS PATIENT IDENTIFICATION AND TARGET ENGAGEMENT IN CLINICAL STUDIES · GrantIndex